questionsmedicales.fr
Composés hétérocycliques
Composés hétéromonocycliques
Azoles
Imidazoles
Imidazolidines
Imidazolidines : Questions médicales fréquentes
Diagnostic
5
Intoxication
Imidazolidines
Tests de toxicologie
Imidazolidines
Marqueurs biologiques
Imidazolidines
Évaluation clinique
Imidazolidines
Symptômes
5
Effets neurologiques
Imidazolidines
Réactions allergiques
Imidazolidines
Système digestif
Imidazolidines
Exposition prolongée
Imidazolidines
Prévention
5
Prévention
Imidazolidines
Formations
Imidazolidines
Équipements de protection
Imidazolidines
Réglementation
Imidazolidines
Sensibilisation
Imidazolidines
Traitements
5
Traitement
Imidazolidines
Symptômes neurologiques
Imidazolidines
Hospitalisation
Imidazolidines
Soins de soutien
Imidazolidines
Complications
5
Complications
Imidazolidines
Dommages permanents
Imidazolidines
Dépendance
Imidazolidines
Suivi médical
Imidazolidines
Réversibilité
Imidazolidines
Facteurs de risque
5
Facteurs de risque
Imidazolidines
Vulnérabilité
Imidazolidines
Environnements industriels
Imidazolidines
Prédispositions génétiques
Imidazolidines
Personnes âgées
Imidazolidines
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Imidazolidines : Questions médicales les plus fréquentes",
"headline": "Imidazolidines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Imidazolidines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-02",
"dateModified": "2026-06-21",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Imidazolidines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Imidazoles",
"url": "https://questionsmedicales.fr/mesh/D007093",
"about": {
"@type": "MedicalCondition",
"name": "Imidazoles",
"code": {
"@type": "MedicalCode",
"code": "D007093",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.129.308"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Imidazolidine-2-thione",
"alternateName": "Ethylenethiourea",
"url": "https://questionsmedicales.fr/mesh/D005031",
"about": {
"@type": "MedicalCondition",
"name": "Imidazolidine-2-thione",
"code": {
"@type": "MedicalCode",
"code": "D005031",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.129.308.432.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Hydantoïnes",
"alternateName": "Hydantoins",
"url": "https://questionsmedicales.fr/mesh/D006827",
"about": {
"@type": "MedicalCondition",
"name": "Hydantoïnes",
"code": {
"@type": "MedicalCode",
"code": "D006827",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.129.308.432.555"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Allantoïne",
"alternateName": "Allantoin",
"url": "https://questionsmedicales.fr/mesh/D000481",
"about": {
"@type": "MedicalCondition",
"name": "Allantoïne",
"code": {
"@type": "MedicalCode",
"code": "D000481",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.129.308.432.555.105"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Dantrolène",
"alternateName": "Dantrolene",
"url": "https://questionsmedicales.fr/mesh/D003620",
"about": {
"@type": "MedicalCondition",
"name": "Dantrolène",
"code": {
"@type": "MedicalCode",
"code": "D003620",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.129.308.432.555.287"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Méphénytoïne",
"alternateName": "Mephenytoin",
"url": "https://questionsmedicales.fr/mesh/D008617",
"about": {
"@type": "MedicalCondition",
"name": "Méphénytoïne",
"code": {
"@type": "MedicalCode",
"code": "D008617",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.129.308.432.555.620"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Phénytoïne",
"alternateName": "Phenytoin",
"url": "https://questionsmedicales.fr/mesh/D010672",
"about": {
"@type": "MedicalCondition",
"name": "Phénytoïne",
"code": {
"@type": "MedicalCode",
"code": "D010672",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.129.308.432.555.730"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Thiohydantoïnes",
"alternateName": "Thiohydantoins",
"url": "https://questionsmedicales.fr/mesh/D013867",
"about": {
"@type": "MedicalCondition",
"name": "Thiohydantoïnes",
"code": {
"@type": "MedicalCode",
"code": "D013867",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.129.308.432.555.868"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "3-Phényl-2-thiohydantoïne",
"alternateName": "Phenylthiohydantoin",
"url": "https://questionsmedicales.fr/mesh/D010669",
"about": {
"@type": "MedicalCondition",
"name": "3-Phényl-2-thiohydantoïne",
"code": {
"@type": "MedicalCode",
"code": "D010669",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.129.308.432.555.868.650"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "3-Phényl-2-thiohydantoïne",
"alternateName": "Phenylthiohydantoin",
"url": "https://questionsmedicales.fr/mesh/D010669",
"about": {
"@type": "MedicalCondition",
"name": "3-Phényl-2-thiohydantoïne",
"code": {
"@type": "MedicalCode",
"code": "D010669",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.129.308.432.555.868.650"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Imidazolidines",
"alternateName": "Imidazolidines",
"code": {
"@type": "MedicalCode",
"code": "D048289",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Joel T Mague",
"url": "https://questionsmedicales.fr/author/Joel%20T%20Mague",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, Tulane University, New Orleans, LA 70118, USA."
}
},
{
"@type": "Person",
"name": "Ming Guo",
"url": "https://questionsmedicales.fr/author/Ming%20Guo",
"affiliation": {
"@type": "Organization",
"name": "Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China."
}
},
{
"@type": "Person",
"name": "Daiying Zuo",
"url": "https://questionsmedicales.fr/author/Daiying%20Zuo",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, 110016, China. Electronic address: zuodaiying@163.com."
}
},
{
"@type": "Person",
"name": "Xin Zhai",
"url": "https://questionsmedicales.fr/author/Xin%20Zhai",
"affiliation": {
"@type": "Organization",
"name": "Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China. Electronic address: zhaixin_syphu@126.com."
}
},
{
"@type": "Person",
"name": "Tuncer Hökelek",
"url": "https://questionsmedicales.fr/author/Tuncer%20H%C3%B6kelek",
"affiliation": {
"@type": "Organization",
"name": "Department of Physics, Hacettepe University, 06800 Beytepe, Ankara, Turkey."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Recent advances in the synthesis of highly substituted imidazolidines.",
"datePublished": "2024-09-26",
"url": "https://questionsmedicales.fr/article/39328874",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1039/d4ra06010e"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ring-Opening Reactions of Imidazolidines and Hexahydropyrimidines with Grignard Reagents.",
"datePublished": "2024-10-17",
"url": "https://questionsmedicales.fr/article/39415746",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.joc.4c01769"
}
},
{
"@type": "ScholarlyArticle",
"name": "Copper-catalyzed reaction of aziridine for the synthesis of substituted imidazolidine and imidazolidinone.",
"datePublished": "2023-09-29",
"url": "https://questionsmedicales.fr/article/37841205",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fchem.2023.1272034"
}
},
{
"@type": "ScholarlyArticle",
"name": "Reactivity and reaction pathways of peroxymonosulfate and peroxydisulfate with neonicotinoid insecticides.",
"datePublished": "2023-11-10",
"url": "https://questionsmedicales.fr/article/37976950",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.watres.2023.120852"
}
},
{
"@type": "ScholarlyArticle",
"name": "Supramolecular assembly activated single-molecule phosphorescence resonance energy transfer for near-infrared targeted cell imaging.",
"datePublished": "2024-06-05",
"url": "https://questionsmedicales.fr/article/38839843",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41467-024-49238-5"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétéromonocycliques",
"item": "https://questionsmedicales.fr/mesh/D006573"
},
{
"@type": "ListItem",
"position": 4,
"name": "Azoles",
"item": "https://questionsmedicales.fr/mesh/D001393"
},
{
"@type": "ListItem",
"position": 5,
"name": "Imidazoles",
"item": "https://questionsmedicales.fr/mesh/D007093"
},
{
"@type": "ListItem",
"position": 6,
"name": "Imidazolidines",
"item": "https://questionsmedicales.fr/mesh/D048289"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Imidazolidines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Imidazolidines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-08-26",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Imidazolidines",
"description": "Comment diagnostiquer une intoxication aux imidazolidines ?\nQuels tests sont utilisés pour détecter les imidazolidines ?\nQuels symptômes indiquent une exposition aux imidazolidines ?\nY a-t-il des marqueurs biologiques pour les imidazolidines ?\nComment évaluer la gravité d'une intoxication ?",
"url": "https://questionsmedicales.fr/mesh/D048289#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Imidazolidines",
"description": "Quels sont les symptômes courants des imidazolidines ?\nLes imidazolidines provoquent-elles des effets neurologiques ?\nPeut-on avoir des réactions allergiques aux imidazolidines ?\nLes imidazolidines affectent-elles le système digestif ?\nY a-t-il des symptômes à long terme d'exposition ?",
"url": "https://questionsmedicales.fr/mesh/D048289#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Imidazolidines",
"description": "Comment prévenir l'exposition aux imidazolidines ?\nY a-t-il des formations pour manipuler les imidazolidines ?\nQuels équipements de protection sont nécessaires ?\nLes imidazolidines sont-elles réglementées ?\nComment sensibiliser aux risques des imidazolidines ?",
"url": "https://questionsmedicales.fr/mesh/D048289#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Imidazolidines",
"description": "Quel est le traitement de l'intoxication aux imidazolidines ?\nDes antidotes existent-ils pour les imidazolidines ?\nComment gérer les symptômes neurologiques ?\nLe traitement nécessite-t-il une hospitalisation ?\nQuels soins de soutien sont recommandés ?",
"url": "https://questionsmedicales.fr/mesh/D048289#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Imidazolidines",
"description": "Quelles complications peuvent survenir après une intoxication ?\nLes imidazolidines peuvent-elles causer des dommages permanents ?\nY a-t-il des risques de dépendance aux imidazolidines ?\nComment surveiller les complications post-intoxication ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D048289#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Imidazolidines",
"description": "Qui est à risque d'exposition aux imidazolidines ?\nLes enfants sont-ils plus vulnérables aux imidazolidines ?\nQuels environnements augmentent le risque d'exposition ?\nY a-t-il des prédispositions génétiques aux effets des imidazolidines ?\nLes personnes âgées sont-elles plus à risque ?",
"url": "https://questionsmedicales.fr/mesh/D048289#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une intoxication aux imidazolidines ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'historique d'exposition et les symptômes cliniques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les imidazolidines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests toxicologiques spécifiques peuvent être réalisés sur des échantillons biologiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une exposition aux imidazolidines ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des troubles neurologiques, des nausées et des vertiges."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs biologiques pour les imidazolidines ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de marqueurs biologiques spécifiques pour ces composés."
}
},
{
"@type": "Question",
"name": "Comment évaluer la gravité d'une intoxication ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'évaluation se fait par l'examen clinique et les résultats des tests de laboratoire."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants des imidazolidines ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des maux de tête, des nausées, et des troubles de la vision."
}
},
{
"@type": "Question",
"name": "Les imidazolidines provoquent-elles des effets neurologiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent causer des effets tels que des convulsions et des troubles de la coordination."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des réactions allergiques aux imidazolidines ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des réactions allergiques peuvent survenir, bien que rares, avec des éruptions cutanées."
}
},
{
"@type": "Question",
"name": "Les imidazolidines affectent-elles le système digestif ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent provoquer des nausées, vomissements et douleurs abdominales."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes à long terme d'exposition ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une exposition prolongée peut entraîner des troubles cognitifs et des problèmes de mémoire."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'exposition aux imidazolidines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des équipements de protection lors de la manipulation de ces composés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des formations pour manipuler les imidazolidines ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des formations spécifiques sont recommandées pour les travailleurs exposés."
}
},
{
"@type": "Question",
"name": "Quels équipements de protection sont nécessaires ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des gants, des lunettes de protection et des masques respiratoires sont conseillés."
}
},
{
"@type": "Question",
"name": "Les imidazolidines sont-elles réglementées ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, leur utilisation est souvent réglementée par des lois sur les substances chimiques."
}
},
{
"@type": "Question",
"name": "Comment sensibiliser aux risques des imidazolidines ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des campagnes de sensibilisation peuvent informer sur les dangers et les précautions."
}
},
{
"@type": "Question",
"name": "Quel est le traitement de l'intoxication aux imidazolidines ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut l'élimination de l'exposition et le soutien symptomatique."
}
},
{
"@type": "Question",
"name": "Des antidotes existent-ils pour les imidazolidines ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas d'antidote spécifique pour les imidazolidines."
}
},
{
"@type": "Question",
"name": "Comment gérer les symptômes neurologiques ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes neurologiques peuvent être gérés par des médicaments anticonvulsivants."
}
},
{
"@type": "Question",
"name": "Le traitement nécessite-t-il une hospitalisation ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une hospitalisation peut être nécessaire en cas de symptômes graves ou persistants."
}
},
{
"@type": "Question",
"name": "Quels soins de soutien sont recommandés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les soins de soutien incluent l'hydratation et le suivi des fonctions vitales."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir après une intoxication ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications neurologiques et respiratoires peuvent survenir après une intoxication."
}
},
{
"@type": "Question",
"name": "Les imidazolidines peuvent-elles causer des dommages permanents ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une exposition prolongée peut entraîner des dommages neurologiques permanents."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de dépendance aux imidazolidines ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les imidazolidines ne sont généralement pas associées à un risque de dépendance."
}
},
{
"@type": "Question",
"name": "Comment surveiller les complications post-intoxication ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier est essentiel pour surveiller les complications potentielles."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'exposition aux imidazolidines ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les travailleurs en laboratoire et ceux manipulant des produits chimiques sont à risque."
}
},
{
"@type": "Question",
"name": "Les enfants sont-ils plus vulnérables aux imidazolidines ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les enfants peuvent être plus vulnérables en raison de leur taille et métabolisme."
}
},
{
"@type": "Question",
"name": "Quels environnements augmentent le risque d'exposition ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les environnements industriels et de recherche augmentent le risque d'exposition."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions génétiques aux effets des imidazolidines ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des prédispositions génétiques peuvent influencer la sensibilité aux effets toxiques."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus à risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées peuvent être plus à risque en raison de la fragilité accrue."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 21/06/2026
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Department of Chemistry, Tulane University, New Orleans, LA 70118, USA.
Publications dans "Imidazolidines" :
3-Isobutyl-5,5-di-phenyl-imidazolidine-2,4-dione.
IUCrData
2022-06-10
3-(2-Bromo-eth-yl)-5,5-di-phenyl-imidazolidine-2,4-dione.
IUCrData
2023-01-26
Crystal structure, Hirshfeld surface analysis and inter-action energy and DFT studies of 1-(1,3-benzo-thia-zol-2-yl)-3-(2-hy-droxy-eth-yl)imidazolidin-2-one.
Acta crystallographica. Section E, Crystallographic communications
2020-02-14
Crystal structure, Hirshfeld surface analysis, calculations of crystal voids, inter-action energy and energy frameworks as well as density functional theory (DFT) calculations of 3-[2-(morpholin-4-yl)eth-yl]-5,5-di-phenyl-imidazolidine-2,4-dione.
Acta crystallographica. Section E, Crystallographic communications
2024-03-26
3 publications dans cette catégorie
Affiliations :
Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Publications dans "Imidazolidines" :
3 publications dans cette catégorie
Affiliations :
Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, 110016, China. Electronic address: zuodaiying@163.com.
Publications dans "Imidazolidines" :
3 publications dans cette catégorie
Affiliations :
Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China. Electronic address: zhaixin_syphu@126.com.
Publications dans "Imidazolidines" :
3 publications dans cette catégorie
Affiliations :
Department of Physics, Hacettepe University, 06800 Beytepe, Ankara, Turkey.
Publications dans "Imidazolidines" :
Crystal structure, Hirshfeld surface analysis and inter-action energy and DFT studies of 5,5-diphenyl-1,3-bis-(prop-2-yn-1-yl)imidazolidine-2,4-dione.
Acta crystallographica. Section E, Crystallographic communications
2019-06-04
Crystal structure, Hirshfeld surface analysis and inter-action energy and DFT studies of 1-(1,3-benzo-thia-zol-2-yl)-3-(2-hy-droxy-eth-yl)imidazolidin-2-one.
Acta crystallographica. Section E, Crystallographic communications
2020-02-14
Crystal structure, Hirshfeld surface analysis, calculations of crystal voids, inter-action energy and energy frameworks as well as density functional theory (DFT) calculations of 3-[2-(morpholin-4-yl)eth-yl]-5,5-di-phenyl-imidazolidine-2,4-dione.
Acta crystallographica. Section E, Crystallographic communications
2024-03-26
2 publications dans cette catégorie
Affiliations :
Department of Chemistry, School of Science, Kwansei Gakuin University, Sanda, Japan.
Publications dans "Imidazolidines" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry, School of Science, Kwansei Gakuin University, Sanda, Japan.
Publications dans "Imidazolidines" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry, School of Science, Kwansei Gakuin University, Sanda, Japan.
JST-PRESTO, Chiyoda, Japan.
Publications dans "Imidazolidines" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Medicinal Chemistry, Drug Sciences Research Center, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco.
Publications dans "Imidazolidines" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Medicinal Chemistry, Drug Sciences Research Center, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco.
Publications dans "Imidazolidines" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Medicinal Chemistry, Faculty of Clinical Pharmacy, 21 September University, Yemen.
Publications dans "Imidazolidines" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Medicinal Chemistry, Drug Sciences Research Center, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco.
Publications dans "Imidazolidines" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
Publications dans "Imidazolidines" :
2 publications dans cette catégorie
Affiliations :
Department of Medicinal Chemistry and Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44, West Wenhua Road, 250012, Jinan, Shandong, PR China.
Publications dans "Imidazolidines" :
2 publications dans cette catégorie
Affiliations :
Department of Medicinal Chemistry and Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44, West Wenhua Road, 250012, Jinan, Shandong, PR China. Electronic address: haofangcn@sdu.edu.cn.
Publications dans "Imidazolidines" :
2 publications dans cette catégorie
Affiliations :
Department of Medicinal Chemistry, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland.
Publications dans "Imidazolidines" :
2 publications dans cette catégorie
Affiliations :
Laboratoire de Chimie Organique Appliquée, Université Sidi Mohamed Ben Abdallah, Faculté des Sciences et Techniques, Route d'Immouzzer, BP 2202, Fez, Morocco.
Publications dans "Imidazolidines" :
Crystal structure, Hirshfeld surface analysis and inter-action energy and DFT studies of 5,5-diphenyl-1,3-bis-(prop-2-yn-1-yl)imidazolidine-2,4-dione.
Acta crystallographica. Section E, Crystallographic communications
2019-06-04
Crystal structure, Hirshfeld surface analysis, calculations of crystal voids, inter-action energy and energy frameworks as well as density functional theory (DFT) calculations of 3-[2-(morpholin-4-yl)eth-yl]-5,5-di-phenyl-imidazolidine-2,4-dione.
Acta crystallographica. Section E, Crystallographic communications
2024-03-26
2 publications dans cette catégorie
Affiliations :
Laboratoire de Chimie Organique Appliquée, Université Sidi Mohamed Ben Abdallah, Faculté des Sciences et Techniques, Route d'Immouzzer, BP 2202, Fez, Morocco.
Publications dans "Imidazolidines" :
Crystal structure, Hirshfeld surface analysis and inter-action energy and DFT studies of 5,5-diphenyl-1,3-bis-(prop-2-yn-1-yl)imidazolidine-2,4-dione.
Acta crystallographica. Section E, Crystallographic communications
2019-06-04
Crystal structure, Hirshfeld surface analysis, calculations of crystal voids, inter-action energy and energy frameworks as well as density functional theory (DFT) calculations of 3-[2-(morpholin-4-yl)eth-yl]-5,5-di-phenyl-imidazolidine-2,4-dione.
Acta crystallographica. Section E, Crystallographic communications
2024-03-26
2 publications dans cette catégorie
Affiliations :
Faculté des Sciences Appliquées Ait Melloul, Université Ibn Zohr, Agadir, Morocco.
Laboratoire de Chimie Organique Hétérocyclique URAC 21, Pôle de Compétence Pharmacochimie, Av. Ibn Battouta, BP 1014, Faculté des Sciences, Université Mohammed V, Rabat, Morocco.
Publications dans "Imidazolidines" :
2 publications dans cette catégorie
Affiliations :
İlke Education and Health Foundation, Cappadocia University, Cappadocia Vocational College, The Medical Imaging Techniques Program, 50420 Mustafapaşa, Ürgüp, Nevşehir, Turkey.
Publications dans "Imidazolidines" :
Imidazolidine is a saturated heterocycle with a cyclic aminal core that can be found in natural products and biologically active molecules. Additionally, these heterocyclic compounds have been utilize...
We herein report an unprecedented ring-opening of unstrained cyclic aminals such as imidazolidines and hexahydropyrimidines by the use of Grignard and cuprate reagents to give secondary sulfonamides b...
Herein we report a copper-catalyzed synthesis of imidazolidine by employing the reaction of aziridine with imine. The reaction smoothly provided a diverse range of 2-substituted imidazolidines with hi...
Neonicotinoid insecticides (NNIs), which have been detected across diverse aquatic environments, have sparked substantial concerns regarding their potential adverse ecological and health risks. In thi...
Pure organic phosphorescence resonance energy transfer is a research hotspot. Herein, a single-molecule phosphorescence resonance energy transfer system with a large Stokes shift of 367 nm and near-in...
A bis(imidazolidine)-derived NCN nickel-pincer complex (...
The new chiral ligands...
Substituted imidazolidinetriones (IZTs) have been identified as potent inhibitors of pyruvate carboxylase (PC) through an in silico screening approach. Alkyl 2-(2,4,5-trioxo-3-substituted imidazolidin...
2,3-Indole-fused 1,4-diazocines represent a new family of indole alkaloid compounds and are difficult to access by the reported protocols. Herein, we report a copper-catalyzed decarboxylative cyclizat...
The development of a palladium catalyst that has enhanced catalytic performance, such as low aluminum cocatalyst loading, good copolymerization ability, high molecular weight, and excellent solubility...